Eli Lilly and Company
COMBINATION THERAPY

Last updated:

Abstract:

A method of treating a cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of an anti-N3pGlu Abeta antibody, an anti-Abeta antibody, or an antibody fragment that binds Amyloid beta and is covalently attached to a polyethylene glycol molecule, in combination with an effective amount of an anti-Tau antibody.

Status:
Application
Type:

Utility

Filling date:

24 Mar 2021

Issue date:

30 Sep 2021